Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655273> ?p ?o ?g. }
Showing items 1 to 80 of
80
with 100 items per page.
- W4385655273 endingPage "e3972537" @default.
- W4385655273 startingPage "e3972537" @default.
- W4385655273 abstract "Topic: 13. Myeloma and other monoclonal gammopathies - Biology & Translational Research Background: The immunomodulatory drugs (IMiDs) have made a profound difference in the treatment of multiple myeloma (MM). Lenalidomide (LND) is chiral compound with two enantiomers and one enantiomer may have different pharmacologic action than the other. For a given chiral drug, until proven otherwise, it is right to think of the two enantiomers as two different drugs with unique properties. Aims: This study aimed to explore efficacy of lenalidomide (R) - (+) and (S) - (-) enantiomers in human multiple myeloma cell line. Methods: H929 myeloma cell line model was designed to understand the potential differences in chirality of the R and S form of LND enantiomers and racemate in multiple myeloma cell line. We report the first biological evaluation of lenalidomide in racemic and in both (R)- and (S)-enantiomerically pure forms against (in vitro) H929 cells of multiple myeloma (MM) using an annexin V assay. Results: It was observed that at 48 hours S-LND treated cells demonstrated significant reduction in the metabolic activity at 10 and 20 µg/mL and profound morphological changes. Cell cycle analysis showed cells in S and G2/M phase were decreased suggesting that all of the drugs can arrest cells at G1 cell cycle phase. We demonstrate (S) - (-) enantiomers of lenalidomide inhibited the growth of H929 MM cells without any in-vivo activation. Summary/Conclusion: The study concludes that (S) - (-) enantiomers of lenalidomide noted more potent agent which could have both the anti-cancerous and immunomodulatory activity.Keywords: Imids, Cell line, Multiple myeloma" @default.
- W4385655273 created "2023-08-09" @default.
- W4385655273 creator A5021518210 @default.
- W4385655273 creator A5030105349 @default.
- W4385655273 creator A5037976340 @default.
- W4385655273 creator A5046943925 @default.
- W4385655273 creator A5059502961 @default.
- W4385655273 creator A5061006768 @default.
- W4385655273 creator A5061288741 @default.
- W4385655273 creator A5078268148 @default.
- W4385655273 creator A5078682094 @default.
- W4385655273 date "2023-08-01" @default.
- W4385655273 modified "2023-10-14" @default.
- W4385655273 title "PB2083: IN-VITRO EVALUATION OF LENALIDOMIDE ENANTIOMERS AGAINST HUMAN MULTIPLE MYELOMA CELL LINE" @default.
- W4385655273 doi "https://doi.org/10.1097/01.hs9.0000975128.39725.37" @default.
- W4385655273 hasPublicationYear "2023" @default.
- W4385655273 type Work @default.
- W4385655273 citedByCount "0" @default.
- W4385655273 crossrefType "journal-article" @default.
- W4385655273 hasAuthorship W4385655273A5021518210 @default.
- W4385655273 hasAuthorship W4385655273A5030105349 @default.
- W4385655273 hasAuthorship W4385655273A5037976340 @default.
- W4385655273 hasAuthorship W4385655273A5046943925 @default.
- W4385655273 hasAuthorship W4385655273A5059502961 @default.
- W4385655273 hasAuthorship W4385655273A5061006768 @default.
- W4385655273 hasAuthorship W4385655273A5061288741 @default.
- W4385655273 hasAuthorship W4385655273A5078268148 @default.
- W4385655273 hasAuthorship W4385655273A5078682094 @default.
- W4385655273 hasBestOaLocation W43856552731 @default.
- W4385655273 hasConcept C185592680 @default.
- W4385655273 hasConcept C202751555 @default.
- W4385655273 hasConcept C203014093 @default.
- W4385655273 hasConcept C207001950 @default.
- W4385655273 hasConcept C2776063141 @default.
- W4385655273 hasConcept C2776364478 @default.
- W4385655273 hasConcept C486523 @default.
- W4385655273 hasConcept C502942594 @default.
- W4385655273 hasConcept C54355233 @default.
- W4385655273 hasConcept C55493867 @default.
- W4385655273 hasConcept C71240020 @default.
- W4385655273 hasConcept C71924100 @default.
- W4385655273 hasConcept C81885089 @default.
- W4385655273 hasConcept C86803240 @default.
- W4385655273 hasConcept C98274493 @default.
- W4385655273 hasConceptScore W4385655273C185592680 @default.
- W4385655273 hasConceptScore W4385655273C202751555 @default.
- W4385655273 hasConceptScore W4385655273C203014093 @default.
- W4385655273 hasConceptScore W4385655273C207001950 @default.
- W4385655273 hasConceptScore W4385655273C2776063141 @default.
- W4385655273 hasConceptScore W4385655273C2776364478 @default.
- W4385655273 hasConceptScore W4385655273C486523 @default.
- W4385655273 hasConceptScore W4385655273C502942594 @default.
- W4385655273 hasConceptScore W4385655273C54355233 @default.
- W4385655273 hasConceptScore W4385655273C55493867 @default.
- W4385655273 hasConceptScore W4385655273C71240020 @default.
- W4385655273 hasConceptScore W4385655273C71924100 @default.
- W4385655273 hasConceptScore W4385655273C81885089 @default.
- W4385655273 hasConceptScore W4385655273C86803240 @default.
- W4385655273 hasConceptScore W4385655273C98274493 @default.
- W4385655273 hasIssue "S3" @default.
- W4385655273 hasLocation W43856552731 @default.
- W4385655273 hasLocation W43856552732 @default.
- W4385655273 hasOpenAccess W4385655273 @default.
- W4385655273 hasPrimaryLocation W43856552731 @default.
- W4385655273 hasRelatedWork W1981457057 @default.
- W4385655273 hasRelatedWork W1983855168 @default.
- W4385655273 hasRelatedWork W2020692772 @default.
- W4385655273 hasRelatedWork W2140679508 @default.
- W4385655273 hasRelatedWork W2464301138 @default.
- W4385655273 hasRelatedWork W2748952813 @default.
- W4385655273 hasRelatedWork W2783092814 @default.
- W4385655273 hasRelatedWork W2899084033 @default.
- W4385655273 hasRelatedWork W3126730168 @default.
- W4385655273 hasRelatedWork W3217566318 @default.
- W4385655273 hasVolume "7" @default.
- W4385655273 isParatext "false" @default.
- W4385655273 isRetracted "false" @default.
- W4385655273 workType "article" @default.